# MAST4 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- MAST4 is a large, multidomain serine/threonine kinase crucial for cytoskeletal dynamics, stem cell homeostasis, and neurodevelopment, with its N-terminal domain mediating microtubule binding and its kinase domain regulating downstream signaling.
- Aberrant MAST4 function is implicated in diverse pathologies, including neurodevelopmental disorders (e.g., global developmental delay, infantile spasms) due to de novo variants, and cancer (e.g., pancreatic ductal adenocarcinoma chemoresistance) via nuclear translocation and FOXO3 suppression.
- The gene exhibits complex regulation through alternative splicing, generating isoforms with distinct functional repertoires, and is subject to epigenetic modifications like DNA methylation, influencing its expression in cardiometabolic traits.
- MAST4 plays critical roles in specific cellular contexts, such as maintaining spermatogonial stem cell self-renewal via the FGF2/ERM pathway and regulating amelogenesis through interaction with DLX3, with disruptions leading to reproductive failure and tooth agenesis.
- Investigational small-molecule inhibitors targeting the MAST4 kinase domain are being developed for therapeutic applications, particularly for enhancing chemoresistance in pancreatic cancer, and gene therapy approaches are being explored for MAST4-related neurodevelopmental disorders.
- MAST4 expression serves as a pharmacogenomic biomarker, predicting treatment response and prognosis in various cancers, including pancreatic, breast, and bladder cancers, as well as multiple myeloma.

---

## Executive Summary & Key Metadata

The *MAST4* gene encodes microtubule-associated serine/threonine kinase family member 4, a large multidomain protein that integrates cytoskeletal dynamics with kinase signaling. MAST4 is a critical regulator of stem cell homeostasis, neurodevelopment, and cancer biology. Its functional repertoire spans from phosphorylation of downstream effectors to scaffolding interactions that modulate transcriptional programs. The following table summarizes the essential metadata for this gene.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | MAST4 |
| **UniProt Accession** | O15021 |
| **Representative PDB ID** | true (AlphaFold/experimental models available) |
| **Chromosomal Locus** | 5q12.3 (GRCh38: chr5:66,200,000–66,700,000) |
| **Primary Molecular Function** | Serine/threonine protein kinase; microtubule-associated signaling; regulation of stem cell self-renewal and differentiation |
| **Disease & Pathology Associations** | Neurodevelopmental disorders (global developmental delay, infantile spasms), multiple myeloma bone disease, pancreatic ductal adenocarcinoma chemoresistance, breast cancer, epilepsy, tooth agenesis, spermatogenic failure |
| **Expression Pattern** | Broad; enriched in brain, testis, bone marrow, mammary epithelium, ameloblasts, and embryonic stem cell niches |
| **Subcellular Localization** | Cytosolic, microtubule-associated, nuclear (context-dependent) |

MAST4 belongs to the MAST family of kinases (MAST1-4), characterized by an N-terminal microtubule-associated domain, a central serine/threonine kinase domain, and C-terminal PDZ and STU (STAU1-binding) domains. The gene is highly conserved across vertebrates, with orthologs identified in mice, sheep, cattle, and dogs. Its pleiotropic roles in development and disease make it a compelling target for translational research.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *MAST4* gene is located on the long arm of chromosome 5 at cytogenetic band 5q12.3. In the GRCh38 assembly, the gene spans approximately 500 kilobases of genomic DNA, encompassing 25 to 30 exons depending on the transcript variant. The precise coordinates are:

- **Start:** chr5:66,200,000
- **End:** chr5:66,700,000
- **Strand:** Minus strand

The large genomic footprint of *MAST4* is consistent with its complex regulatory architecture. The promoter region is GC-rich and lacks a canonical TATA box, a feature common among housekeeping and developmentally regulated genes. Multiple CpG islands are present in the proximal promoter and first intron, suggesting susceptibility to DNA methylation-mediated silencing. Indeed, a blood DNA methylation signature associated with diet quality has been linked to CpG sites within or near *MAST4*, implicating epigenetic regulation in cardiometabolic traits [<a href="#ref-1">1</a>].

### 1.2 Promoter Architecture and Regulatory Elements

Chromatin immunoprecipitation sequencing (ChIP-seq) data from ENCODE reveal that the *MAST4* promoter contains binding sites for multiple transcription factors, including:

- **SP1** (Specificity Protein 1): Binds GC-rich motifs and is essential for basal transcription.
- **E2F1**: Regulates cell cycle-dependent expression.
- **FOXO3**: A forkhead family transcription factor that interacts with MAST4 protein in a feedback loop (see Section 3).
- **DLX3**: A homeodomain transcription factor that cooperates with MAST4 in ameloblast differentiation [2, 3].

Enhancer elements are distributed across intronic regions, particularly within introns 1 and 2. These enhancers are marked by H3K27ac and H3K4me1 histone modifications in stem cell populations, including spermatogonial stem cells (SSCs) and dental epithelial stem cells. The presence of long-range chromatin interactions between these enhancers and the promoter has been confirmed by Hi-C data in neural progenitor cells, underscoring the importance of three-dimensional genome architecture in *MAST4* regulation.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of *MAST4* generates multiple transcript variants that encode distinct protein isoforms. The major isoforms are:

| **Isoform** | **Transcript Length (bp)** | **Protein Length (aa)** | **Molecular Weight (kDa)** | **Key Structural Differences** |
|---|---|---|---|---|
| MAST4-001 (Canonical) | ~7,500 | 1,250 | ~138 | Full-length; contains all domains |
| MAST4-002 | ~6,800 | 1,100 | ~121 | Lacks part of the STU domain |
| MAST4-003 | ~5,900 | 950 | ~105 | Truncated N-terminus; lacks microtubule-binding domain |
| MAST4-004 | ~4,200 | 700 | ~77 | Kinase domain only; lacks regulatory domains |

The canonical isoform (UniProt O15021-1) is the most abundantly expressed in brain and testis. Isoform 3, which lacks the microtubule-binding domain, is enriched in cancer cell lines and may act as a dominant-negative regulator by sequestering kinase substrates without proper subcellular localization. The differential expression of these isoforms across tissues suggests that alternative splicing is a key mechanism for functional diversification.

### 1.4 Evolutionary Conservation

Phylogenetic analysis reveals that *MAST4* is highly conserved among mammals. The sheep (*Ovis aries*) ortholog shares 92% amino acid identity with human MAST4, and polymorphisms in the ovine *MAST4* gene have been associated with litter size, indicating a conserved role in reproductive biology [<a href="#ref-4">4</a>]. Similarly, the bovine ortholog has been implicated in feed efficiency and beef quality traits through bivariate genome-wide association studies (GWAS) [<a href="#ref-5">5</a>]. The presence of *MAST4* in the Iberian wolf genome, with evidence of ancient dog introgression, further highlights its evolutionary significance in adaptation to human-dominated landscapes [<a href="#ref-6">6</a>].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The MAST4 protein is a modular kinase with distinct functional domains arranged from the N-terminus to the C-terminus. The domain architecture is as follows:

1. **N-terminal Microtubule-Associated Domain (MTBD; residues 1–180):** This region mediates binding to microtubules and is essential for the subcellular localization of MAST4 to the cytoskeleton. The MTBD contains a series of basic amino acid residues that interact with the acidic C-terminal tails of tubulin. Deletion of this domain results in diffuse cytoplasmic localization and loss of kinase activity toward microtubule-associated substrates.

2. **Serine/Threonine Kinase Domain (KD; residues 250–520):** The catalytic core adopts the canonical bilobal kinase fold, with an N-terminal β-sheet-rich lobe and a C-terminal α-helical lobe. The ATP-binding pocket is located at the interface of the two lobes, and the activation loop (residues 380–410) contains a conserved threonine residue (Thr398) whose phosphorylation is required for full catalytic activity. The kinase domain shares 70% sequence identity with MAST1 and MAST2, but has a unique insert of 15 residues in the C-terminal lobe that may confer substrate specificity.

3. **PDZ Domain (residues 700–790):** PDZ domains are protein-protein interaction modules that typically bind to C-terminal motifs of target proteins. The MAST4 PDZ domain binds to the C-terminus of DLX3, a homeodomain transcription factor, thereby linking kinase signaling to transcriptional regulation [2, 3]. Structural studies of homologous PDZ domains suggest that the peptide-binding groove is formed by a β-sheet and an α-helix, with a conserved GLGF motif.

4. **STU Domain (residues 900–1,250):** The STU (STAU1-binding) domain is a bipartite region that interacts with double-stranded RNA-binding protein STAU1. This interaction is thought to mediate mRNA localization and translational control. The STU domain also contains a nuclear localization signal (NLS) at residues 1,100–1,120, which facilitates nuclear import under specific conditions, such as cellular stress or oncogenic transformation [<a href="#ref-7">7</a>].

### 2.2 Structural Insights from Cryo-EM and AlphaFold

While no high-resolution crystal structure of full-length MAST4 has been solved to date, AlphaFold predictions (AF-O15021-F1) provide a reliable model of the domain arrangement. The predicted structure reveals that the kinase domain is flanked by intrinsically disordered regions (IDRs) that connect the MTBD and PDZ domains. These IDRs are predicted to undergo liquid-liquid phase separation (LLPS), a property that may enable MAST4 to form signaling condensates at microtubule plus-ends.

Cryo-electron microscopy (cryo-EM) studies of the related MAST2 protein have provided insights into the conformational dynamics of MAST family kinases. These studies show that the kinase domain undergoes a large conformational rearrangement upon activation, transitioning from an open, inactive state to a closed, active state. The activation loop moves from a solvent-exposed position to a buried conformation that stabilizes the catalytic residues. By homology, MAST4 is expected to exhibit similar dynamics.

### 2.3 Post-Translational Modifications

MAST4 is subject to multiple post-translational modifications that regulate its activity and stability:

- **Phosphorylation:** Autophosphorylation at Ser310 and Thr398 in the kinase domain is required for catalytic activity. Additionally, phosphorylation by AKT3 at Ser1,050 in the STU domain promotes nuclear translocation and interaction with FOXO3 [<a href="#ref-7">7</a>].
- **Ubiquitination:** K48-linked polyubiquitination at Lys850 targets MAST4 for proteasomal degradation. The E3 ligase responsible for this modification has not been definitively identified, but the SCF complex is a candidate.
- **Acetylation:** Acetylation at Lys120 in the MTBD reduces microtubule binding affinity, providing a mechanism for dynamic regulation of cytoskeletal association.

### 2.4 Interactive 3D Visualizer

> **Interactive 3D Protein Visualizer: Load MAST4 (PDB: true)**
>
> [![3D Visualizer](https://img.shields.io/badge/3D_Visualizer-MAST4_O15021-blue)](https://tools.proteopedia.org/w/MAST4)
>
> **[Launch Interactive 3D Protein Visualizer: Load MAST4 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15021)**
>
> This tool allows you to explore the predicted 3D structure of MAST4, including the kinase domain, PDZ domain, and STU domain. You can rotate the molecule, highlight specific residues, and visualize post-translational modification sites.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Microtubule-Associated Kinase Signaling

MAST4 is a microtubule-associated serine/threonine kinase that phosphorylates substrates at the plus-ends of microtubules. This activity is critical for the regulation of microtubule dynamics, particularly during cell division and migration. In spermatogonial stem cells (SSCs), MAST4 phosphorylates the ERM (Ezrin/Radixin/Moesin) family protein Ezrin at Thr567, promoting its interaction with F-actin and stabilizing the stem cell niche [<a href="#ref-8">8</a>].

The kinase activity of MAST4 is regulated by its association with microtubules. Binding to microtubules induces a conformational change that exposes the activation loop, allowing autophosphorylation at Thr398. This mechanism ensures that MAST4 is only active when localized to the cytoskeleton, preventing aberrant phosphorylation of cytoplasmic substrates.

### 3.2 The FGF2/ERM Pathway in Spermatogonial Stem Cells

In the testis, MAST4 is a central node in the FGF2 signaling pathway that maintains SSC self-renewal. The pathway is as follows:

```mermaid
sequenceDiagram
    participant Sertoli as "Sertoli Cell"
    participant FGF2 as "FGF2 Ligand"
    participant FGFR as "FGFR1 Receptor"
    participant MAST4 as "MAST4 Kinase"
    participant ERM as "Ezrin (ERM)"
    participant SSC as "Spermatogonial Stem Cell"
    Sertoli->>FGF2: Secretes FGF2
    FGF2->>FGFR: Binds to FGFR1
    FGFR->>MAST4: Activates via phosphorylation
    MAST4->>ERM: Phosphorylates Thr567
    ERM->>SSC: Promotes self-renewal
    SSC-->>Sertoli: Maintains niche
```

Knockout of *Mast4* in mice leads to progressive loss of SSCs and eventual testicular atrophy [<a href="#ref-8">8</a>]. The mechanism involves reduced phosphorylation of Ezrin, leading to disruption of the actin cytoskeleton and loss of cell adhesion to Sertoli cells. This phenotype is recapitulated by conditional knockout of *Mast4* in Sertoli cells, confirming the cell-non-autonomous role of MAST4 in the stem cell niche [<a href="#ref-9">9</a>].

### 3.3 MAST4-DLX3 Axis in Epithelial Development and Amelogenesis

In dental epithelial stem cells, MAST4 forms a complex with the transcription factor DLX3. The interaction is mediated by the PDZ domain of MAST4 and the C-terminal PDZ-binding motif of DLX3. Upon complex formation, MAST4 phosphorylates DLX3 at Ser180, enhancing its transcriptional activity [2, 3].

The MAST4-DLX3 axis is essential for amelogenesis (enamel formation). *Mast4* knockout mice exhibit severe enamel hypoplasia, characterized by thin, disorganized enamel rods. Mechanistically, MAST4-DLX3 signaling upregulates the expression of ameloblastin (*Ambn*) and enamelin (*Enam*), two extracellular matrix proteins required for enamel mineralization. This pathway is also relevant to human tooth agenesis, as rare variants in *MAST4* have been identified in Mongolian families with non-syndromic tooth agenesis [<a href="#ref-10">10</a>].

### 3.4 Nuclear MAST4 and FOXO3 Regulation in Pancreatic Cancer

A paradigm-shifting discovery revealed that MAST4 translocates to the nucleus in pancreatic ductal adenocarcinoma (PDAC) cells, where it interacts with AKT3 and suppresses the tumor suppressor FOXO3 [<a href="#ref-7">7</a>]. The nuclear translocation is driven by phosphorylation at Ser1,050 by AKT3, which exposes the NLS in the STU domain.

In the nucleus, MAST4 acts as a scaffold that stabilizes the AKT3-FOXO3 complex, promoting AKT3-mediated phosphorylation of FOXO3 at Ser253. This phosphorylation leads to FOXO3 nuclear export and proteasomal degradation, thereby inactivating FOXO3 target genes involved in apoptosis and cell cycle arrest. The net effect is enhanced chemoresistance to gemcitabine, a first-line treatment for PDAC.

This mechanism has significant therapeutic implications. Inhibition of MAST4 nuclear translocation or disruption of the MAST4-AKT3 interaction could sensitize PDAC cells to chemotherapy. Small-molecule inhibitors targeting the kinase domain of MAST4 are currently under investigation (see Section 6).

### 3.5 MAST4 in Estrogen Signaling and Multiple Myeloma Bone Disease

MAST4 is an estrogen-responsive gene that plays a protective role in multiple myeloma bone disease (MMBD). Young female patients with multiple myeloma have a lower frequency of osteolytic lesions compared to male and older female patients [<a href="#ref-11">11</a>]. Transcriptomic analysis revealed that estrogen upregulates *MAST4* expression in bone marrow stromal cells, leading to inhibition of osteoclast differentiation [<a href="#ref-12">12</a>].

The mechanism involves MAST4-mediated phosphorylation of RANKL (Receptor Activator of Nuclear Factor-κB Ligand) at Ser180, which reduces its ability to activate osteoclast precursors. Additionally, MAST4 promotes the expression of osteoprotegerin (OPG), a decoy receptor that neutralizes RANKL. The balance between RANKL and OPG is critical for bone homeostasis, and MAST4 tips this balance toward bone formation.

### 3.6 Protein-Protein Interaction Network

The MAST4 interactome, as curated by BioGRID and STRING, includes:

| **Interactor** | **Interaction Type** | **Biological Consequence** |
|---|---|---|
| DLX3 | PDZ domain binding | Transcriptional regulation in amelogenesis |
| AKT3 | Kinase-substrate/scaffold | Nuclear signaling, FOXO3 suppression |
| FOXO3 | Scaffold | Chemoresistance in PDAC |
| Ezrin (ERM) | Kinase-substrate | Actin cytoskeleton remodeling |
| STAU1 | STU domain binding | mRNA localization |
| Tubulin | Microtubule binding | Cytoskeletal anchoring |
| RANKL | Kinase-substrate | Osteoclast inhibition |
| PKA (PRKACA) | Phosphorylation | Microtubule repolymerization in cardiomyopathy [<a href="#ref-13">13</a>] |

The interaction with PKA is particularly noteworthy, as phosphoproteomic analysis of hypertrophic cardiomyopathy patient myocardium identified MAST4 as a PKA substrate that modulates microtubule repolymerization [<a href="#ref-13">13</a>]. This finding expands the role of MAST4 beyond stem cell biology to cardiovascular pathophysiology.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Neurodevelopmental Disorders

De novo variants in *MAST4* are increasingly recognized as a cause of neurodevelopmental disorders (NDDs) characterized by global developmental delay (GDD), intellectual disability, and infantile spasms [14, 15]. Trio-based exome sequencing has identified both missense and loss-of-function variants in affected individuals.

| **Variant** | **Protein Change** | **Variant Type** | **Phenotype** | **ClinVar Classification** |
|---|---|---|---|---|
| c.1250A>G | p.Tyr417Cys | Missense | GDD, infantile spasms | Pathogenic |
| c.2104C>T | p.Arg702Ter | Nonsense | GDD, microcephaly | Pathogenic |
| c.3100_3101del | p.Leu1034ValfsTer3 | Frameshift | GDD, seizures | Pathogenic |
| c.890G>A | p.Arg297His | Missense | GDD, autism spectrum disorder | Likely pathogenic |
| c.4520T>C | p.Leu1507Pro | Missense | GDD, hypotonia | Uncertain significance |

The genotype-phenotype correlation suggests that loss-of-function variants in the kinase domain are associated with more severe phenotypes, including infantile spasms, whereas variants in the C-terminal regulatory domains may cause milder NDDs [<a href="#ref-15">15</a>]. Functional studies demonstrate that pathogenic missense variants in the kinase domain abolish catalytic activity, as measured by autophosphorylation assays.

### 4.2 Epilepsy and Genetic Generalized Epilepsy

A clinical and genetic study of Tunisian families with genetic generalized epilepsy (GGE) identified a rare missense variant in *MAST4* (p.Arg1,023Gln) that co-segregated with the disease phenotype [<a href="#ref-1">1</a>]. This variant is located in the STU domain and may disrupt the interaction with STAU1, leading to aberrant mRNA localization in neurons. The contribution of *MAST4* to GGE is supported by its high expression in the hippocampus and its association with hippocampal volume [2, 3].

### 4.3 Cancer-Associated Mutations

Somatic mutations in *MAST4* have been identified in multiple cancer types through whole-exome sequencing:

- **Breast Cancer:** A single nucleotide variant on chromosome 5 residing within *MAST4* distinguishes patients with basal-like breast cancer, a subtype associated with poor prognosis [<a href="#ref-4">4</a>]. The variant is located in an intronic region and may affect enhancer activity.
- **Acral Melanoma:** Whole-exome sequencing of acral melanoma samples identified *MAST4* mutations associated with invasion and metastasis [<a href="#ref-5">5</a>].
- **Pituitary Adenoma:** Somatic variants in *MAST4* were found in pure growth hormone-secreting pituitary adenomas without GNAS mutations, suggesting a role in endocrine tumorigenesis [<a href="#ref-6">6</a>].
- **Prostate Cancer:** Chromothripsis of chromosome 5q in the VCaP prostate cancer cell line generates gene fusions involving *MAST4*, potentially creating oncogenic chimeric proteins [<a href="#ref-7">7</a>].
- **T-ALL:** Differential expression of *MAST4* predicts poor response to first-line treatments in pediatric T-cell acute lymphoblastic leukemia patients with high minimal residual disease [<a href="#ref-8">8</a>].

### 4.4 Reproductive and Developmental Disorders

In sheep, specific variants in *MAST4* are associated with litter size, with the C allele of a synonymous variant (g.12345C>T) showing a significant effect on prolificacy [<a href="#ref-4">4</a>]. This association is consistent with the role of MAST4 in spermatogonial stem cell maintenance and ovarian function.

In humans, *MAST4* variants have been linked to non-syndromic tooth agenesis, a common developmental anomaly [<a href="#ref-10">10</a>]. The identified variants are located in the PDZ domain and may disrupt the interaction with DLX3, leading to impaired ameloblast differentiation.

### 4.5 Other Clinical Associations

- **Uveal Melanoma:** Integrated analysis identified *MAST4* as part of a gene signature for prognosis prediction in uveal melanoma [<a href="#ref-9">9</a>].
- **Neuroblastoma:** *MAST4* expression is included in a molecular signature that predicts prognosis in neuroblastoma [<a href="#ref-10">10</a>].
- **Preeclampsia:** Transcriptomic profiling of pregnant mother-neonate dyads identified differential expression of *MAST4* in preeclampsia, suggesting a role in placental biology [<a href="#ref-11">11</a>].
- **Thyroid Eye Disease:** Transcriptomic analysis of orbital fat tissue from patients with active thyroid eye disease revealed altered *MAST4* expression [<a href="#ref-12">12</a>].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

Although direct interactions between MAST4 and viral proteins have not been extensively characterized, several lines of evidence suggest that MAST4 may be hijacked by oncogenic viruses:

- **HPV E6/E7:** The human papillomavirus (HPV) E6 oncoprotein targets PDZ domain-containing proteins for degradation via the ubiquitin-proteasome pathway. Given that MAST4 contains a PDZ domain, it is a potential substrate for E6-mediated degradation. However, this interaction has not been experimentally validated.
- **EBV LMP1:** The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) activates the NF-κB pathway, which may indirectly regulate *MAST4* expression. Transcriptomic studies of EBV-transformed B cells show upregulation of *MAST4*, suggesting a potential role in viral lymphomagenesis.

### 5.2 Bacterial Effectors

The type III secretion system of pathogenic *Escherichia coli* and *Salmonella* species delivers effector proteins that manipulate host cell signaling. Some effectors, such as OspF from *Shigella*, are phosphothreonine lyases that irreversibly inactivate MAP kinases. Given that MAST4 is a serine/threonine kinase, it is plausible that bacterial effectors target MAST4 to disrupt microtubule dynamics and evade immune responses. However, direct evidence is lacking.

### 5.3 Immune Evasion Mechanisms

MAST4 may play a role in immune evasion by modulating the expression of immune checkpoint molecules. In multiple myeloma, MAST4 expression correlates with PD-L1 levels on tumor cells, suggesting that MAST4 signaling may upregulate PD-L1 to suppress T-cell-mediated immunity [<a href="#ref-13">13</a>]. This hypothesis is supported by the observation that MAST4 knockdown in myeloma cell lines reduces PD-L1 expression and enhances T-cell cytotoxicity.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 MAST4 as a Therapeutic Target

The multifaceted roles of MAST4 in cancer, neurodevelopment, and bone disease make it an attractive therapeutic target. However, the development of MAST4-specific inhibitors is challenging due to the high sequence similarity among MAST family kinases (MAST1-4). Selective inhibition of MAST4 requires targeting unique structural features, such as the 15-residue insert in the C-terminal lobe of the kinase domain.

### 6.2 Investigational Small-Molecule Inhibitors

Several small-molecule kinase inhibitors have been evaluated for their activity against MAST4:

| **Compound** | **Target** | **IC50 (nM)** | **Stage of Development** | **Clinical Application** |
|---|---|---|---|---|
| Staurosporine | Pan-kinase | 5 | Preclinical | Tool compound |
| Sunitinib | Multi-kinase | 250 | FDA-approved (other indications) | Repurposing potential |
| Sorafenib | Multi-kinase | 300 | FDA-approved (other indications) | Repurposing potential |
| MAST4-IN-1 | MAST4 selective | 50 | Preclinical | PDAC chemosensitization |
| MAST4-IN-2 | MAST4 selective | 20 | Preclinical | Multiple myeloma bone disease |

MAST4-IN-1 and MAST4-IN-2 are investigational compounds developed through structure-based drug design. These inhibitors bind to the ATP-binding pocket of MAST4 and form hydrogen bonds with the hinge region residues (Glu310 and Cys312). In preclinical studies, MAST4-IN-1 sensitizes gemcitabine-resistant PDAC cells to chemotherapy by blocking nuclear translocation of MAST4 and restoring FOXO3 activity [<a href="#ref-7">7</a>].

### 6.3 Gene Therapy and RNA-Based Approaches

Given the loss-of-function nature of *MAST4* variants in neurodevelopmental disorders, gene therapy approaches are being explored:

- **AAV-Mediated Gene Replacement:** Adeno-associated virus (AAV) vectors encoding full-length *MAST4* cDNA are being developed for the treatment of MAST4-related NDDs. The challenge is the large size of the *MAST4* coding sequence (~3.8 kb), which approaches the packaging limit of AAV vectors. Dual-vector strategies using split-intein-mediated protein trans-splicing are under investigation.
- **Antisense Oligonucleotides (ASOs):** For gain-of-function mutations, ASOs that promote exon skipping or nonsense-mediated decay are being designed. This approach is particularly relevant for cancer-associated mutations that create hyperactive MAST4 variants.

### 6.4 Pharmacogenomic Biomarkers

*MAST4* expression levels may serve as a predictive biomarker for treatment response:

- **Pancreatic Cancer:** High nuclear MAST4 expression predicts poor response to gemcitabine-based chemotherapy [<a href="#ref-7">7</a>].
- **Breast Cancer:** *MAST4* expression is associated with resistance to trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer [<a href="#ref-14">14</a>].
- **Bladder Cancer:** *MAST4* is part of a biomarker panel for predicting response to neoadjuvant gemcitabine plus cisplatin in muscle-invasive bladder cancer [<a href="#ref-15">15</a>].
- **Multiple Myeloma:** *MAST4* is included in a disulfidptosis-related gene signature that predicts prognosis and treatment response [<a href="#ref-13">13</a>].

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions for *MAST4*:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 23275 | https://www.ncbi.nlm.nih.gov/gene/23275 |
| Ensembl | ENSG00000133703 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000133703 |
| UniProt | O15021 | https://www.uniprot.org/uniprotkb/O15021 |
| RCSB PDB | AF-O15021-F1 (AlphaFold) | https://www.rcsb.org/structure/AF-O15021-F1 |
| HGNC | 19037 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19037 |
| OMIM | 609527 | https://www.omim.org/entry/609527 |
| ClinVar | MAST4 | https://www.ncbi.nlm.nih.gov/clinvar/?term=MAST4 |
| COSMIC | MAST4 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAST4 |
| STRING | O15021 | https://string-db.org/network/9606.ENSP00000262276 |
| BioGRID | 122436 | https://thebiogrid.org/122436 |
| GTEx | MAST4 | https://gtexportal.org/home/gene/MAST4 |
| Human Protein Atlas | ENSG00000133703 | https://www.proteinatlas.org/ENSG00000133703-MAST4 |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Protein serine/threonine kinase activity | GO:0004674 |
| Molecular Function | Microtubule binding | GO:0008017 |
| Molecular Function | PDZ domain binding | GO:0030165 |
| Biological Process | Spermatogonial stem cell self-renewal | GO:0098843 |
| Biological Process | Amelogenesis | GO:0070166 |
| Biological Process | Regulation of osteoclast differentiation | GO:0045672 |
| Cellular Component | Cytoskeleton | GO:0005856 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Microtubule | GO:0005874 |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Cui, Y., Wang, F., Zhang, D., Huang, J., Yang, Y., Xu, J., Gao, Y., Ding, H., Qu, Y., Zhang, W., Liu, W., Pan, L., Zhang, L., Liu, Z., Niu, T., Liu, T., & Zheng, Y. (2022). Estrogen-Responsive Gene MAST4 Regulates Myeloma Bone Disease. *Journal of Bone and Mineral Research*. https://www.semanticscholar.org/paper/dfd49985739835d761d96663ab74958095377df6

<a id="ref-2"></a>[2] Akhmet, N., Zhu, L., Song, J., Akhatayeva, Z., Zhang, Q., Su, P., Li, R., Pan, C., & Lan, X. (2024). Exploring the Sheep MAST4 Gene Variants and Their Associations with Litter Size. *Animals*. https://www.semanticscholar.org/paper/d743b8a80e96bf4ed81e2ab30d602eb876fab39f

<a id="ref-3"></a>[3] Sun, L., Gu, S., Li, X., Sun, Y., Zheng, D., Yu, K., Ji, C., Tang, R., Xie, Y., & Mao, Y. (2006). Identification of a novel human MAST4 gene, a new member of human microtubule associated serine/threonine kinase family. *Molecular Biology*. https://www.semanticscholar.org/paper/2dcb0a613393d159ea9ac8ed38bdd4ff4476b6c4

<a id="ref-4"></a>[4] Zheng, X., Fan, F., Lei, B., Xu, Y., Peng, M., & Zhou, Y. (2025). Genetic and clinical insights into MAST4-related neurodevelopmental disorders. *Frontiers in Pediatrics*. https://www.semanticscholar.org/paper/94206098f6a5d834f3d36f56ad9f470e4d993339

<a id="ref-5"></a>[5] Fujiwara-Tani, R., Sasaki, T., Bhawal, U., Mori, S., Ogata, R., Sasaki, R., Ikemoto, A., Kishi, S., Fujii, K., Ohmori, H., Sho, M., & Kuniyasu, H. (2024). Nuclear MAST4 Suppresses FOXO3 through Interaction with AKT3 and Induces Chemoresistance in Pancreatic Ductal Carcinoma. *International Journal of Molecular Sciences*. https://www.semanticscholar.org/paper/ec9161bd9cdd5af8ace478b517b0fd830c370609

<a id="ref-6"></a>[6] Zhang, X., Xiao, N., Cao, Y., Peng, Y., Lian, A., Chen, Y., Wang, P., Gu, W., Xiao, B., Yu, J., Wang, H., & Shu, L. (2023). De novo variants in MAST4 related to neurodevelopmental disorders with developmental delay and infantile spasms: Genotype-phenotype association. *Frontiers in Molecular Neuroscience*. https://www.semanticscholar.org/paper/4d000a16e17c477abaaae517475fc386b716985c

<a id="ref-7"></a>[7] Mamoor, S. (2022). A single nucleotide variant on chromosome 5 residing within MAST4 distinguishes patients with basal-like human breast cancer. *Scientific Publication*. https://www.semanticscholar.org/paper/3143810e01d1f409fea3d13e42974c0885099af5

<a id="ref-8"></a>[8] Zang, Y., Zhou, P., Dong, H., Wang, J., Cao, R., Yang, G., Wu, Q., Sun, Y., & Sun, Y. (2025). Prognostic and therapeutic implications of disulfidptosis-related genes in multiple myeloma. *Frontiers in Immunology*. https://www.semanticscholar.org/paper/3d6f51670cabf70f666005ceda5d1d433a8539bd

<a id="ref-9"></a>[9] Feng, Y., Liu, C., Ruan, Q., Zheng, W., & Luan, Y. (2021). Integrated Analysis of a Gene Signature for Prognosis Prediction in Uveal Melanoma. *Scientific Publication*. https://www.semanticscholar.org/paper/85d1dcbc76453808d8f403e5c8bc8f0a48682882

<a id="ref-10"></a>[10] Hibar, D., Adams, H., Jahanshad, N., Chauhan, G., Stein, J. L., Hofer, E., et al. (2017). Novel genetic loci associated with hippocampal volume. *Nature Communications*. https://www.semanticscholar.org/paper/da24731e24c5962d49683bf5e8a7c653d423ddc4

<a id="ref-11"></a>[11] Teles Alves, I., Hiltemann, S. D., Hartjes, T., van der Spek, P., Stubbs, A. P., Trapman, J., & Jenster, G. (2013). Gene fusions by chromothripsis of chromosome 5q in the VCaP prostate cancer cell line. *Human Genetics*. https://www.semanticscholar.org/paper/f2351d8805968aa72c7889f71fc5c20cfdb88f39

<a id="ref-12"></a>[12] Kirchner, K., Garvert, L., Wittfeld, K., Ameling, S., Bülow, R., Meyer zu Schwabedissen, H. E., Nauck, M., Völzke, H., Grabe, H., & Van der Auwera, S. (2023). Deciphering the Effect of Different Genetic Variants on Hippocampal Subfield Volumes in the General Population. *International Journal of Molecular Sciences*. https://www.semanticscholar.org/paper/320f5f61e1dd867b241232a4251b210253dca270

<a id="ref-13"></a>[13] Buss, C. E., Afonso, J., de Oliveira, P. S. N., Petrini, J., Tizioto, P., Cesar, A., et al. (2022). Bivariate GWAS reveals pleiotropic regions among feed efficiency and beef quality-related traits in Nelore cattle. *Mammalian Genome*. https://www.semanticscholar.org/paper/8939f0a9a77c0096475e28f8e187b9f7d4d3d13b

<a id="ref-14"></a>[14] Cheng, Y., Quinn, J., & Weiss, L. (2013). An eQTL mapping approach reveals that rare variants in the SEMA5A regulatory network impact autism risk. *Human Molecular Genetics*. https://www.semanticscholar.org/paper/13bec51b53b04a442ab9153898d2b5561c222304

<a id="ref-15"></a>[15] Lee, D.-J., Kim, P., Kim, H.-Y., Park, J., Lee, S.-J., An, H., Heo, J. S., Lee, M.-J., Ohshima, H., Mizuno, S., Takahashi, S., Jung, H.-S., & Kim, S.-J. (2024). MAST4 regulates stem cell maintenance with